|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 331.95 CHF | -0.55% |
|
+0.67% | +1.28% |
| 09:00am | Roche, Nurix Therapeutics Close Deal for Global Partnership for Bexobrutideg | MT |
| 20/07 | Wall Street's Patience Runs Thin |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 33TCr | |||||
| 1,04800Cr | |||||
| 60TCr | |||||
| 45TCr | |||||
| 28TCr | |||||
| 26TCr |
- Stock Market
- Stocks
- ROP Stock
- Charts Roche Holding AG
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition